Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sodium butyrate in preparation of hypoxic pulmonary hypertension control medicines

A technology of pulmonary hypertension and sodium butyrate, applied in drug combination, active ingredients of anhydride/acid/halide, cardiovascular system diseases, etc., can solve the problem of drug administration, unclear toxic and negative effects, limited effect, receptor antagonism Efficiency and use methods are not clear, to achieve the effect of prevention and treatment of hypoxic pulmonary hypertension, prevention and treatment of proliferation and hypertrophy, and low price

Inactive Publication Date: 2012-12-19
ARMY MEDICAL UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Focusing on improving the function of endothelial cells to secrete vasoactive substances, the methods to prevent and treat hypoxic pulmonary hypertension include: ① direct inhalation of NO gas, although effective, is not easy to carry and take at any time; ② use of NO precursors, such as L-arginine However, studies have shown that hypoxia can inhibit the expression and catalytic activity of endothelial nitric oxide synthase (eNOS), which is specifically expressed in endothelial cells. Therefore, if the reduced activity of eNOS under hypoxic conditions is not corrected, only NO precursors are increased. effect is limited
③The use of ET-1 receptor antagonists, but not only the administration method and toxic side effects are not clear, but also the receptor antagonism efficiency and the way of use are not clear
④Gene therapy, through the transfection of eNOS expression vector and ET-1 inhibitory vector, regulates the secretory function of hypoxic endothelial cells, but the safety and feasibility of clinical application of this method are not clear
In addition, the current technical means and existing research have not paid attention to and solved the regulation of the homeostatic balance of endothelial cells secreting ET-1 and NO
However, there is no report about the use of sodium butyrate in the prevention and treatment of hypoxic pulmonary hypertension.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sodium butyrate in preparation of hypoxic pulmonary hypertension control medicines
  • Application of sodium butyrate in preparation of hypoxic pulmonary hypertension control medicines
  • Application of sodium butyrate in preparation of hypoxic pulmonary hypertension control medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Dissolve 2.2 g of sodium butyrate with a purity of more than 98% in 10 mL of normal saline to prepare a drug for preventing and treating hypoxic pulmonary hypertension.

Embodiment 2

[0026] Dissolve 3.52g of sodium butyrate with a purity of more than 98% in 10mL of normal saline to prepare a drug for the prevention and treatment of hypoxic pulmonary hypertension.

[0027] Of course, sodium butyrate can be added with corresponding pharmaceutical carriers according to clinical needs, and can exist in the form of tablets, pills, capsules, aqueous solutions and other preparations.

experiment example 1

[0029] Experimental example 1: Effect of sodium butyrate on NO secretion from hypoxic human umbilical vein endothelial cells (HUVEC) and human pulmonary artery endothelial cells (HPAEC)

[0030] Human umbilical vein endothelial cells (HUVEC, cell line) were purchased from ATCC, USA. After recovery, cells were washed twice with PBS, and complete medium (high-glucose DMEM (purchased from Gibco) containing 10% fetal bovine serum (purchased from Hyclone), penicillin and streptomycin each 100 U / ml (purchased from Gibco)) was added, and the cells were cultured in normal Incubator (CO 2 5%) for routine culture at 37°C.

[0031] Human pulmonary artery endothelial cells (HPAEC, primary cells) were purchased from Invitrogen, and complete medium (composed of medium M-200, 50× endothelial cell nutrient solution LSGS, 100 U / ml of penicillin and streptomycin) was added. Cells were cultured in an ordinary culture incubator (CO 2 5%) for routine culture at 37°C.

[0032]The above-mentio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of sodium butyrate in the preparation of hypoxic pulmonary hypertension control medicines. The sodium butyrate has an inhibition effect on the secretion of endothelin-1 of hypoxic endothelial cells and has a promotion effect on the secretion of NO in the hypoxic endothelial cells, so the hypoxic pulmonary hypertension disease is controlled. The sodium butyrate has the advantages of stable property, easy dissolving in aqueous solutions, direct oral taking after dissolving, convenient administration, convenient carrying, non-toxicity and harmlessness, and low price.

Description

technical field [0001] The invention relates to a new drug application of sodium butyrate, in particular to the application of sodium butyrate in the preparation of drugs for the prevention and treatment of hypoxic pulmonary hypertension. Background technique [0002] Pulmonary hypertension (PH) is a group of diseases characterized by a progressive increase in pulmonary vascular resistance, leading to right ventricular failure and death, with a high rate of disability and mortality (75% of patients died within 5 years after diagnosis, The average survival period is 1.9 years, and 75% of patients are concentrated in the 20-40 age group), which can be called "cancer" in cardiovascular diseases. Hypoxic pulmonary hypertension (hypoxic pulmonary hypertension HPH) is the most common type of PH, and it is also the focus of prevention and treatment of pulmonary hypertension in my country. First of all, hypoxic pulmonary hypertension is the central link in the pathogenesis of acute...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/19A61P9/12
Inventor 谭小玲高钰琪黄小勇陈德伟冯岚
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com